Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHRS NASDAQ:REPL NASDAQ:SNDX NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$11.94-4.3%$14.13$6.00▼$20.50$621.24M0.97324,388 shs164,093 shsREPLReplimune Group$5.73-4.7%$6.75$2.68▼$17.00$447.28M0.513.91 million shs1.33 million shsSNDXSyndax Pharmaceuticals$15.55-5.0%$12.77$8.58▼$22.50$1.34B0.722.23 million shs1.71 million shsTVRDTvardi Therapeutics$33.88-4.3%$26.60$8.13▼$36.71$317.79M0.2532,598 shs39,705 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research-3.18%-11.17%+2.80%-2.19%+53.32%REPLReplimune Group+0.33%+3.44%+14.48%-38.55%-42.04%SNDXSyndax Pharmaceuticals+4.07%+1.11%+26.21%+59.71%-10.64%TVRDTvardi Therapeutics+7.80%+16.29%+50.00%+43.79%+3,539,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$11.94-4.3%$14.13$6.00▼$20.50$621.24M0.97324,388 shs164,093 shsREPLReplimune Group$5.73-4.7%$6.75$2.68▼$17.00$447.28M0.513.91 million shs1.33 million shsSNDXSyndax Pharmaceuticals$15.55-5.0%$12.77$8.58▼$22.50$1.34B0.722.23 million shs1.71 million shsTVRDTvardi Therapeutics$33.88-4.3%$26.60$8.13▼$36.71$317.79M0.2532,598 shs39,705 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research-3.18%-11.17%+2.80%-2.19%+53.32%REPLReplimune Group+0.33%+3.44%+14.48%-38.55%-42.04%SNDXSyndax Pharmaceuticals+4.07%+1.11%+26.21%+59.71%-10.64%TVRDTvardi Therapeutics+7.80%+16.29%+50.00%+43.79%+3,539,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHRSGH Research 2.88Moderate Buy$32.00168.01% UpsideREPLReplimune Group 2.10Hold$6.5013.44% UpsideSNDXSyndax Pharmaceuticals 3.00Buy$39.22152.23% UpsideTVRDTvardi Therapeutics 3.00Buy$64.2589.64% UpsideCurrent Analyst Ratings BreakdownLatest TVRD, GHRS, REPL, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025SNDXSyndax PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.009/8/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral9/5/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/4/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$34.008/13/2025GHRSGH ResearchZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/6/2025SNDXSyndax PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/5/2025SNDXSyndax PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$46.00 ➝ $51.008/5/2025SNDXSyndax PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$43.00 ➝ $56.007/30/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight7/23/2025REPLReplimune GroupBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$17.00 ➝ $3.007/23/2025REPLReplimune GroupBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Underperform$27.00 ➝ $2.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ASNDXSyndax Pharmaceuticals$77.93M17.19N/AN/A$3.38 per share4.60TVRDTvardi Therapeutics$7.14M44.51N/AN/A($3.02) per share-11.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)REPLReplimune Group-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)TVRDTvardi Therapeutics-$70.87MN/A0.00∞N/A-678.79%-565.83%-66.71%N/ALatest TVRD, GHRS, REPL, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TVRDTvardi Therapeutics-$0.51-$1.00-$0.49-$1.00N/AN/A8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/A8/7/2025Q1 2026REPLReplimune Group-$0.83-$0.95-$0.12-$0.95$0.50 millionN/A8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHRSGH ResearchN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHRSGH ResearchN/A29.4929.49REPLReplimune Group0.216.946.94SNDXSyndax Pharmaceuticals2.064.714.55TVRDTvardi TherapeuticsN/A4.044.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHRSGH Research56.90%REPLReplimune Group92.53%SNDXSyndax PharmaceuticalsN/ATVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipGHRSGH Research41.60%REPLReplimune Group5.20%SNDXSyndax Pharmaceuticals4.10%TVRDTvardi Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHRSGH Research1052.03 million30.38 millionOptionableREPLReplimune Group21078.06 million74.00 millionOptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableTVRDTvardi Therapeutics809.38 million9.09 millionN/ATVRD, GHRS, REPL, and SNDX HeadlinesRecent News About These CompaniesTvardi Therapeutics (NASDAQ:TVRD) Is In A Good Position To Deliver On Growth PlansAugust 31, 2025 | finance.yahoo.comTvardi Therapeutics (NASDAQ:TVRD) Trading Down 0.9% - Here's WhyAugust 24, 2025 | marketbeat.comTvardi Therapeutics to Participate in the Cantor Global Healthcare ConferenceAugust 21, 2025 | theglobeandmail.comTvardi Therapeutics (NASDAQ:TVRD) Releases Quarterly Earnings Results, Misses Estimates By $0.49 EPSAugust 16, 2025 | marketbeat.comTvardi Therapeutics expects cash to fund operations into Q4 2026August 15, 2025 | msn.comTvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last yearAugust 15, 2025 | msn.comTvardi: Q2 Earnings SnapshotAugust 14, 2025 | timesunion.comTTvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business UpdateAugust 14, 2025 | finance.yahoo.comRaymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform RecommendationJuly 15, 2025 | msn.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | finance.yahoo.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | businesswire.comCantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight RecommendationJuly 12, 2025 | msn.comTvardi Therapeutics Inc News (TVRD) - Investing.comJune 27, 2025 | investing.comTVRD Tvardi Therapeutics, Inc.June 19, 2025 | seekingalpha.comPiper Sandler initiates Tvardi Therapeutics stock with overweight ratingJune 13, 2025 | uk.investing.comRecently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock UpsideJune 12, 2025 | benzinga.comTvardi Therapeutics Inc (TVRD)June 7, 2025 | investing.comTvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary FibrosisMay 27, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025AI Glasses to Replace Smartphones? Meta Is Taking Aim at AppleBy Leo Miller | August 16, 2025TVRD, GHRS, REPL, and SNDX Company DescriptionsGH Research NASDAQ:GHRS$11.94 -0.54 (-4.33%) Closing price 04:00 PM EasternExtended Trading$11.96 +0.02 (+0.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Replimune Group NASDAQ:REPL$5.73 -0.28 (-4.66%) Closing price 04:00 PM EasternExtended Trading$5.72 -0.01 (-0.09%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$15.55 -0.82 (-5.01%) Closing price 04:00 PM EasternExtended Trading$16.13 +0.58 (+3.74%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Tvardi Therapeutics NASDAQ:TVRD$33.88 -1.52 (-4.29%) As of 04:00 PM EasternCara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
